Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States
Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.
Publication Profile
Scopus
Education
Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.
Experience
Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.
Awards and Honors
Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year π (Miller School of Medicine, 2015), the Outstanding Care Award π
(Sarcoma Alliance, 2012), and the Leadership in Clinical Research ποΈ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.
Research Focus
Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.
Publication Top Notes
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours
Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA
Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER